We’ve recently updated our valuation analysis.

NuVasive Valuation

Is NUVA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NUVA?

Other financial metrics that can be useful for relative valuation.

NUVA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.6x
Enterprise Value/EBITDA15.7x
PEG Ration/a

Price to Sales Ratio vs Peers

How does NUVA's PS Ratio compare to its peers?

NUVA PS Ratio vs Peers
The above table shows the PS ratio for NUVA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average1.8x
ITGR Integer Holdings
1.6x5.6%US$2.1b
CNMD CONMED
2.4x8.8%US$2.5b
LIVN LivaNova
2.6x6.2%US$2.7b
ENOV Enovis
0.7x0.5%US$2.6b
NUVA NuVasive
1.9x6.7%US$2.3b

Price-To-Sales vs Peers: NUVA is expensive based on its Price-To-Sales Ratio (1.9x) compared to the peer average (1.8x).


Price to Earnings Ratio vs Industry

How does NUVA's PE Ratio compare vs other companies in the US Medical Equipment Industry?

Price-To-Sales vs Industry: NUVA is good value based on its Price-To-Sales Ratio (1.9x) compared to the US Medical Equipment industry average (3.9x)


Price to Sales Ratio vs Fair Ratio

What is NUVA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NUVA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.9x
Fair PS Ratio4.2x

Price-To-Sales vs Fair Ratio: NUVA is good value based on its Price-To-Sales Ratio (1.9x) compared to the estimated Fair Price-To-Sales Ratio (4.2x).


Share Price vs Fair Value

What is the Fair Price of NUVA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NUVA ($43.62) is trading below our estimate of fair value ($45.91)

Significantly Below Fair Value: NUVA is trading below fair value, but not by a significant amount.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies